Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04102579 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
A Phase 3 study of Chorea, Huntington, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 128
- Enrollment target
- 20
- Study locations
NCT04102579 is a Phase 3 study of Chorea, Huntington that has completed, run by Neurocrine Biosciences. The registered enrollment target is 128 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT04102579, a Phase 3 study of Chorea, Huntington, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 128 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine to treat chorea in participants with Huntington disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Valbenazine
Study Locations (20)
California
- Neurocrine Clinical Site - La Jolla
- Neurocrine Clinical Site - Sacramento
Colorado
- Neurocrine Clinical Site - Aurora
- Neurocrine Clinical Site - Englewood
Florida
- Neurocrine Clinical Site - Gainesville
- Neurocrine Clinical Site - Miami
Illinois
- Neurocrine Clinical Site - Chicago
- Neurocrine Clinical Site - Chicago
Kansas
- Neurocrine Clinical Site - Kansas City
- Neurocrine Clinical Site - Wichita
Massachusetts
- Neurocrine Clinical Site - Boston
- Neurocrine Clinical Site - Boston
Alabama
- Neurocrine Clinical Site - Birmingham
Arkansas
- Neurocrine Clinical Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2019-11-13 |
| Est. Completion | 2021-10-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04102579
The ClinicalTrials.gov registry entry for NCT04102579 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chorea, Huntington appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04102579 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT04102579 about?
NCT04102579 is a clinical study titled "Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease". This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine to treat chorea in participants with Huntington disease.
What is the current status of trial NCT04102579?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 128 participants. The study started on 2019-11-13. Estimated completion is 2021-10-26.
What conditions does trial NCT04102579 study?
This clinical trial studies the following conditions: Chorea, Huntington.
What interventions are being tested in trial NCT04102579?
The interventions under investigation include: Placebo (DRUG), Valbenazine (DRUG).
Who is sponsoring clinical trial NCT04102579?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04102579 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chorea, Huntington
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.